Series A · Biotech
Vaxdyn raises €11m Series A for first human trial of K-VAX
Biovance Capital led the round with a €4m investment, joined by the EIC Fund and public-fund financing managed by Arcano.
Moving the vaccine programme into Phase I
Biovance Capital led Vaxdyn’s €11 million Series A with a €4 million investment. The EIC Fund joined alongside public-fund financing managed by Arcano Partners through Impacto Andalucía Innovación y Desarrollo.
The capital will fund the first-in-human Phase I trial of K-VAX. The vaccine candidate targets antimicrobial-resistant bacteria, including Klebsiella pneumoniae and Acinetobacter baumannii.
Use of funds
Fund the first-in-human Phase I trial of K-VAX
Funding history
Series A · This round€11M